2020
First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial
Hochmair M, Camidge, Kim H, Ahn M, Yang J, Han J, Lee K, Delmonte A, Campelo G, Kim D, Griesinger F, Felip E, Califano R, Spira A, Gettinger S, Tiseo M, Ni Q, Zhang P, Popat S. First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial. Pneumologie 2020, 74: 131-131. DOI: 10.1055/s-0039-3403360.Peer-Reviewed Original Research
2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer
Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer. European Journal Of Cancer 2018, 101: 114-122. PMID: 30053670, DOI: 10.1016/j.ejca.2018.06.033.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeutropeniaSurvival AnalysisTime FactorsTreatment OutcomeConceptsObjective response rateProgression-free survivalCell lung cancerOverall survivalLung cancerAnti-programmed death ligand 1 antibodyGrade III/IV adverse eventsConfirmed objective response rateMedian progression-free survivalPlatinum-based doublet chemotherapyStandard first-line therapyDeath ligand 1 antibodyCell death protein 1Availability of immunotherapyMedian overall survivalFirst-line therapyLigand 1 antibodyDeath protein 1Actionable gene alterationsLong-term survivalDoublet chemotherapyImmunotherapy combinationsNab-PacNab-paclitaxelAdverse events
2017
Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.
Liu S, Camidge D, Gettinger S, Giaccone G, Heist R, Hodi F, Ready N, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. Journal Of Clinical Oncology 2017, 35: 9092-9092. DOI: 10.1200/jco.2017.35.15_suppl.9092.Peer-Reviewed Original ResearchNon-small cell lung cancerOverall response rateAdverse eventsAnti-programmed death ligand 1 antibodyAdvanced non-small cell lung cancerMetastatic non-small cell lung cancerCommon treatment-related grade 3Terms of ORRConfirmed overall response rateGrade 5 adverse eventsStandard first-line therapyTreatment-related grade 3Death ligand 1 antibodyPhase Ib studyTumor antigen releaseFirst-line therapyPhase III studyPlatinum-based chemotherapyCell lung cancerActionable gene alterationsMulti-arm studiesMultiple tumor typesMedian PFSNSCLC ptsPrior chemo84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial
Peters S, Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. 84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Annals Of Oncology 2017, 28: ii29-ii30. DOI: 10.1093/annonc/mdx091.004.Peer-Reviewed Original ResearchAtezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study
Eberhardt W, Garassino M, Rizvi N, Besse B, Jänne P, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017, 71: s1-s125. DOI: 10.1055/s-0037-1598277.Peer-Reviewed Original Research
2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology 2016, 18: 31-41. PMID: 27932067, PMCID: PMC5476941, DOI: 10.1016/s1470-2045(16)30624-6.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsCell lung cancerAdverse eventsObjective responseLung cancerGrade 3Treatment-related serious adverse eventsAnti-PD-1 monotherapyChemotherapy-naive NSCLCTolerable safety profileTreatment-related deathsSerious adverse eventsFirst-line therapyFirst-line treatmentPhase 3 studyUS academic centersFirst-line nivolumabWithdrawal of consentFurther clinical developmentHigh response ratePhase 1Bristol-Myers SquibbCombination nivolumabEligible patientsMedian follow
2013
Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist L, Ireland B, Stinchcombe TE. Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e341s-e368s. PMID: 23649446, PMCID: PMC4694611, DOI: 10.1378/chest.12-2361.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCetuximabErlotinib HydrochlorideGlutamatesGuanineHumansLung NeoplasmsNeoplasm StagingPatient SelectionPemetrexedPlatinum CompoundsProtein Kinase InhibitorsQuinazolinesConceptsStage IV non-small cell lung cancerNon-small cell lung cancerFirst-line therapyPerformance statusNonsquamous histologyLung cancerAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEastern Cooperative Oncology Group (ECOG) PSChest Physicians Lung Cancer GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsCell lung cancer diagnosisReceptor tyrosine kinase inhibitorsClinical patient characteristicsLung cancer guidelinesRole of cetuximabSafety of bevacizumabThird-line settingECOG performance statusGood performance statusPlatinum-based regimensPoor performance status